Gadodiamide administration causes spurious hypocalcemia

Radiology

Volumn 227, Issue 3, 2003, Pages 639-646

  Prince, Martin R ^a   Erel, Hale E ^a   Lent, Richard W ^a   Blumenfeld, Jon ^a,b   Kent, K Craig ^a   Bush, Harry L ^a   Wang, Yi ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROGOSIN INSTITUTE   (United States)

Author keywords

Calcium; Contrast media; Contrast media, effects; Magnetic resonance (MR), contrast media

Indexed keywords

CALCIUM; CONTRAST MEDIUM; CREATININE; GADODIAMIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHILD; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; DIAGNOSTIC IMAGING; FEMALE; HUMAN; HYPOCALCEMIA; INFANT; KIDNEY FUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBOTOMY; PRIORITY JOURNAL;

CALCIUM; CONTRAST MEDIA; CREATININE; FEMALE; GADOLINIUM; GADOLINIUM DTPA; HUMANS; HYPOCALCEMIA; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 0038075480     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2273012007     Document Type: Article

References (22)

1. Normann PT, Froysa A, Svaland M. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. Scand J Clin Lab Invest 1995; 55:421-426.
2. Lin J, Idee J, Port M, et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. J Pharm Biomed Anal 1999; 21: 931-943.
3. VanWagoner M, O'Toole M, Worah D, Leese PT, Quay SC. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol 1991; 26:980-986.
4. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991; 26:975-979.
5. Prince MR, Arnoldus C, Frisoli JF. Nephrotoxicity of high-dose gadolinium compared to iodinated contrast. J Magn Reson Imaging 1996; 6:162-166.
6. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1991; 180:85-89.
7. Runge VM. Safety of magnetic resonance contrast media. Magn Reson Imaging 2001; 12:309-314.
8. Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases. AJR Am J Roentgenol 1996; 167:847-849.
9. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 1999; 10:477-484.
10. Young DS. Effects of drugs on clinical laboratory. 5th ed. Washington, DC: American Association of Clinical Chemists, 2000.
11. Participant Summary Report of the College of American Pathologists Chemistry Survey C-C2001. Northfield, III: College of American Pathologists, 2001; 18.
12. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990; 8:467-481.
13. Chang CA. Magnetic resonance imaging contrast agents: design and physicochemical properties of gadodiamide. Invest Radiol 1993; 28:S21-S27.
14. Periasamy M, White D, deLearie L, et al. The synthesis and screening of nonionic gadolinium III DTPA-bisamide complexes as magnetic resonance imaging contrast agents. Invest Radiol 1991; 26:S217-S220.
15. Tweedle MF, Hagan JJ, Kumar K, Mantha S, Chang CA. Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 1991; 9:409-415.
16. Corot C, Idee JM, Hentsch AM, et al. Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme. JMRI 1998; 8:695-702.
17. Tweedle M. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992; 27(suppl 1):2-6.
18. Le Mignon MM, Chambon C, Warrington S, Davies R, Bonnemain B. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest Radiol 1990; 25:933-937.
19. Corot C, Belleville J, Paul J, Arriel M, Elroy R. In vitro interactions of gadolinium DOTA meglumine and gadolinium DTPA meglumine on hemostasis. Invest Radiol 1988; 23(suppl):5261-5263.
20. Muhler A, Saeed DVM, Brasch RC, Higgins CB. Amelioration of cardiodepressive effects of gadopentetate dimeglumine with addition of ionic calcium. Radiology 1992; 184:159-164.
21. Idee JM, Berthommier C, Boulas V, et al. Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation. Biometals 1998; 11:113-123.
22. Bokenes J, Hustvedt SO, Refsum H. Comparison of cardiovascular changes after administration of gadodiamide injection and gadopentetate dimeglumine in dogs. Acad Radiol 1997; 4:204-209.